VITACOV: Vitamin D Polymorphisms and Severity of COVID-19 Infection

CompletedOBSERVATIONAL
Enrollment

517

Participants

Timeline

Start Date

August 1, 2020

Primary Completion Date

January 1, 2021

Study Completion Date

January 31, 2021

Conditions
COVID-19
Interventions
OTHER

Exposure

Individuals with SARS-CoV-2 exposure and COVID-19 symptoms.

Trial Locations (3)

1649-032

Cardiovascular Center at Universidade de Lisboa, Lisbon

Centro Hospitalar Universitário Lisboa Norte, Lisbon

4200-319

Centro Hospitalar de São João, Porto

All Listed Sponsors
collaborator

Cardiovascular Centre of Universidade de Lisboa (CCUL)

UNKNOWN

collaborator

Faculty of Medicine of Universidade de Lisboa (FMUL)

UNKNOWN

collaborator

Centro Hospitalar Universitário Lisboa Norte

OTHER

collaborator

Centro Hospitalar Universitário São João (CHUSJ)

UNKNOWN

collaborator

CINTESIS - Center for Health Technology and Services Research

UNKNOWN

collaborator

Universidade Nova de Lisboa

OTHER

collaborator

HeartGenetics, Genetics and Biotechnology SA

INDUSTRY

collaborator

Instituto Gulbenkian de Ciência (IGC)

UNKNOWN

lead

University of Lisbon

OTHER

NCT04370808 - VITACOV: Vitamin D Polymorphisms and Severity of COVID-19 Infection | Biotech Hunter | Biotech Hunter